With the incidence of celiac disease expected to triple by 2050, the need for effective therapeutics - preventative, supportive and curative - are becoming more urgent than ever. At AMYRA, we are working hard to incorporate the learnings from the interdisciplinary research presented at this year's ICDS to tackle the complexity of this disease and potentially other peptide-induced health conditions. Our recent clinical proof of concept study clearly demonstrated the applicability of our technology to gluten-related health conditions. It's now time to scale and translate these findings in a big way!
AMYRA Biotech AG was pleased to attend the International Celiac Disease Symposium in Sheffield this year. The event hosted an amazing array of talks on and around the pathophysiology of celiac disease, non-celiac gluten sensitivity and other related health conditions. Was great to reconnect with scientists, gastroenterologists, researchers and patient advocacy groups in the field! To find out more about the research we presented at this year’s poster session, please get in touch! #amyra #gluten #icds #celiacdisease #glutensensitivity #gastroenterology #enzymetherapy #sheffield
Your science is top notch Julian 👏🏽
Well done and congrats to Amyra and team!
Phytomedicine | Public Policy | Hospitality |
3moUpwards and onwards.